Payment overview · 2025
General Payments
$82.19
3 reported records · 2 companies
Healthcare provider profile · identity verified
Ashfaq Saiyed, M.D.
Allopathic & Osteopathic Physicians|General Practice · OCILLA, GA · NPI 1225119407
Verified facts
What the public records show
CMS Open Payments records show Ashfaq Saiyed, M.D. received $82.19 in general payments during 2025 across 3 reported records.
Ardelyx, Inc. accounted for 78.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $64.80 | 78.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.39 | 21.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $82.19 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $64.80 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 633 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 546 | 110 |
| Gabapentin | Gabapentin | 475 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 81 |
| Losartan Potassium | Losartan Potassium | 368 | 67 |
| Potassium Chloride | Potassium Chloride | 359 | 70 |
| Meloxicam | Meloxicam | 348 | 75 |
| Tramadol Hcl | Tramadol Hcl | 345 | 62 |
| Omeprazole | Omeprazole | 320 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 300 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 299 | 66 |
| Metformin Hcl | Metformin Hcl | 293 | 56 |
| Lisinopril | Lisinopril | 281 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 265 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 49 |
| Famotidine | Famotidine | 234 | 54 |
| Furosemide | Furosemide | 214 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 36 |
| Allopurinol | Allopurinol | 162 | 26 |
| Carvedilol | Carvedilol | 159 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 31 |
| Trazodone Hcl | Trazodone Hcl | 147 | 30 |
| Simvastatin | Simvastatin | 145 | 30 |
| Jardiance | Empagliflozin | 144 | 27 |
| Linzess | Linaclotide | 144 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 26 |
| Azithromycin | Azithromycin | 136 | 93 |
| Clonidine Hcl | Clonidine Hcl | 136 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 41 |
| Alprazolam | Alprazolam | 132 | 20 |
| Lovastatin | Lovastatin | 127 | 23 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 125 | 25 |
| Glimepiride | Glimepiride | 121 | 28 |
| Mounjaro | Tirzepatide | 121 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 30 |
| Fenofibrate | Fenofibrate | 104 | 15 |
| Ibuprofen | Ibuprofen | 98 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 95 | 23 |
| Buspirone Hcl | Buspirone Hcl | 90 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 19 |
| Temazepam | Temazepam | 87 | 22 |
| Ezetimibe | Ezetimibe | 85 | 22 |
| Atenolol | Atenolol | 83 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 82 | 16 |
| Pregabalin | Pregabalin | 82 | 17 |
| Myrbetriq | Mirabegron | 78 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 18 |
| Methylprednisolone | Methylprednisolone | 76 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 28 |
| Promethazine Hcl | Promethazine Hcl | 75 | 16 |
| Ozempic | Semaglutide | 70 | 13 |
| Carisoprodol | Carisoprodol | 69 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 49 |
| Eliquis | Apixaban | 67 | 12 |
| Farxiga | Dapagliflozin Propanediol | 67 | 19 |
| Mirtazapine | Mirtazapine | 66 | 12 |
| Montelukast Sodium | Montelukast Sodium | 66 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 65 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 63 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 62 | 15 |
| Colchicine | Colchicine | 62 | suppressed |
| Lorazepam | Lorazepam | 60 | 12 |
| Meclizine Hcl | Meclizine Hcl | 58 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 21 |
| Donepezil Hcl | Donepezil Hcl | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Topiramate | Topiramate | 44 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | suppressed |
| Fluconazole | Fluconazole | 41 | 25 |
| Colesevelam Hcl | Colesevelam Hcl | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 18 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Austedo | Deutetrabenazine | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $82.19 · 3 records | Ardelyx, Inc. | BREZTRI, IBSRELA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error